American health-policy nonprofit guiding public understanding
Weight-loss GLP-1 drugs are expanding beyond injections to pills in the US, UK and UAE. Major manufacturers report rising uptake and ongoing development, with Medicare and NHS access shaping pace and affordability. Private prescriptions and new formulations are widening access while competition accelerates.
Insurers are signaling double‑digit premium increases for 2027 in preliminary rate filings across 16 states and the District of Columbia. Analysts attribute the rise to higher healthcare costs and the expiration of pandemic‑era subsidies, with enrollment shrinking as affordability pressures mount.
Funding for HIV programs has declined sharply, pressuring prevention and community health services while treatment remains more stable. US policy changes and broader donor pullbacks have led to thousands of clinic closures and tens of thousands of job losses, with warnings of longer-term risks to the epidemic.
Donor contributions to HIV programmes have declined, with the 2025 funding level the lowest since 2007. The US remains the largest donor but has reduced its support, while total resources for HIV response have fallen 18% across all sources. UNAIDS warns that declining funding could jeopardise gains in prevention and treatment in Sub-Saharan Africa.
At AIDS 2026 in Rio, a State Department slide showing Africa mislabels countries, carrying an AI watermark. Reuters and others report the error, with the State Department taking responsibility. The issue comes as donor funding for global HIV programs has fallen, prompting questions about sustained commitments and effective aid delivery.
Starbucks and Bank of America are recalibrating GLP-1 weight-loss drug coverage amid rising costs. Starbucks will exclude GLP-1s for weight loss from October for benefits-eligible employees; Bank of America says its GLP-1 program costs exceed $250 million annually and accounts for about 13% of healthcare spend. Other firms weigh limits as utilization climbs.